Top

Cardiovascular Drugs and Therapy

Published in:

01-08-2009

Myocardial Infarct Size-Limiting and Anti-Arrhythmic Effects of Mildronate Orotate in the Rat Heart

Authors: Reinis Vilskersts, Edgars Liepinsh, Janis Kuka, Helena Cirule, Maris Veveris, Ivars Kalvinsh, Maija Dambrova

Published in: Cardiovascular Drugs and Therapy | Issue 4/2009

Abstract

Purpose

Mildronate and orotic acid act as modulators of energy metabolism and are considered as cardioprotective agents. This study was performed to compare the cardioprotective effects of mildronate, orotic acid and mildronate orotate.

Methods

Male Wistar rats received mildronate, orotic acid or mildronate orotate for 14 days. The isolated rat heart infarction and isoproterenol-induced ischemia models were used to test the cardioprotective effects of compounds studied. Experimental arrhythmias were induced by the ligation of the left anterior descending coronary artery for 10 min with subsequent reperfusion or by administration of calcium chloride or aconitine at arrhythmogenic doses.

Results

The data obtained showed a statistically significant decrease of necrotic area in 25% of infarcted rat hearts after 14 days of treatment with mildronate and orotic acid, whereas mildronate orotate decreased the infarct size by 50%. Moreover, we found that the administration of mildronate and its orotate salt decreased the duration and incidence of arrhythmias in experimental arrhythmia models.

Conclusions

The study provides experimental evidence that the combination of orotic acid and mildronate possesses additive pharmacological effects and that mildronate orotate might be considered as a powerful therapeutic agent facilitating recovery from ischemia-reperfusion injury.

Fragasso G. Inhibition of free fatty acids metabolism as a therapeutic target in patients with heart failure. Int J Clin Pract. 2007;61:603–10.PubMedCrossRef

Wang W, Lopaschuk GD. Metabolic therapy for the treatment of ischemic heart disease: reality and expectations. Expert Rev Cardiovasc Ther. 2007;5:1123–34.PubMedCrossRef

Rupp H, Zarain-Herzberg A, Maisch B. The use of partial fatty acid oxidation inhibitors for metabolic therapy of angina pectoris and heart failure. Herz. 2002;27:621–36.PubMedCrossRef

Chandler MP, Chavez PN, McElfresh TA, Huang H, Harmon CS, Stanley WC. Partial inhibition of fatty acid oxidation increases regional contractile power and efficiency during demand-induced ischemia. Cardiovasc Res. 2003;59:143–51.PubMedCrossRef

Fragasso G, Palloshi A, Puccetti P, et al. A randomized clinical trial of trimetazidine, a partial free fatty acid oxidation inhibitor, in patients with heart failure. J Am Coll Cardiol. 2006;48:992–8.PubMedCrossRef

Tafreshi MJ, Fisher E. Ranolazine: a new approach to management of patients with angina. Ann Pharmacother. 2006;40:689–93.PubMedCrossRef

Singh BN, Wadhani N. Antiarrhythmic and proarrhythmic properties of QT-prolonging antianginal drugs. J Cardiovasc Pharmacol Ther. 2004;9:S85–97.PubMedCrossRef

Dambrova M, Liepinsh E, Kalvinsh I. Mildronate: cardioprotective action through carnitine-lowering effect. Trends Cardiovasc Med. 2002;12:275–9.PubMedCrossRef

Sjakste N, Kalvinsh I. Mildronate: an antiischemic drug with multiple indications. Pharmacologyonline. 2006;1:1–18.

10.

Asaka N, Muranaka Y, Kirimoto T, Miyake H. Cardioprotective profile of MET-88, an inhibitor of carnitine synthesis, and insulin during hypoxia in isolated perfused rat hearts. Fundam Clin Pharmacol. 1998;12:158–63.PubMedCrossRef

11.

Simkhovich BZ, Shutenko ZV, Meirena DV, et al. 3-(2, 2, 2-Trimethylhydrazinium) propionate (THP)—a novel gamma-butyrobetaine hydroxylase inhibitor with cardioprotective properties. Biochem Pharmacol. 1988;37:195–202.PubMedCrossRef

12.

Liepinsh E, Vilskersts R, Loca D, et al. Mildronate, an inhibitor of carnitine biosynthesis, induces an increase in gamma-butyrobetaine contents and cardioprotection in isolated rat heart infarction. J Cardiovasc Pharmacol. 2006;48:314–9.PubMedCrossRef

13.

Sesti C, Simkhovich BZ, Kalvinsh I, Kloner RA. Mildronate, a novel fatty acid oxidation inhibitor and antianginal agent, reduces myocardial infarct size without affecting hemodynamics. J Cardiovasc Pharmacol. 2006;47:493–9.PubMed

14.

Hayashi Y, Tajima K, Kirimoto T, Miyake H, Matsuura N. Cardioprotective effects of MET-88, a gamma-butyrobetaine hydroxylase inhibitor, on cardiac dysfunction induced by ischemia/reperfusion in isolated rat hearts. Pharmacology. 2000;61:238–43.PubMedCrossRef

15.

Hadj A, Pepe S, Rosenfeldt F. The clinical application of metabolic therapy for cardiovascular disease. Heart Lung Circ. 2007;16:S56–64.PubMedCrossRef

16.

Kolos G, Williams JF, Hickie JB. Biochemical studies in myocardial hypertrophy and metabolic support of the acutely stressed myocardium. Adv Cardiol. 1974;12:106–15.PubMed

17.

Munsch C, Williams JF, Rosenfeldt FL. The impaired tolerance of the recently infarcted rat heart to cardioplegic arrest: the protective effect of orotic acid. J Mol Cell Cardiol. 1989;21:751–4.PubMedCrossRef

18.

Rosenfeldt FL. Metabolic supplementation with orotic acid and magnesium orotate. Cardiovasc Drugs Ther. 1998;12:147–52.PubMedCrossRef

19.

Yeh T, Rebeyka IM, Jakoi ER, et al. Orotic acid improves left ventricular recovery four days after heterotopic transplantation. Ann Thorac Surg. 1994;58:409–15.PubMedCrossRef

20.

Richards SM, Conyers RA, Fisher JL, Rosenfeldt FL. Cardioprotection by orotic acid: metabolism and mechanism of action. J Mol Cell Cardiol. 1997;29:3239–50.PubMedCrossRef

21.

Stepura OB, Tomaeva FE, Zvereva TV. Orotic acid as a metabolic agent. Vestn Ross Akad Med Nauk 2002:39–41.

22.

Rosenfeldt FL, Richards SM, Lin Z, Pepe S, Conyers RA. Mechanism of cardioprotective effect of orotic acid. Cardiovasc Drugs Ther. 1998;12:159–70.PubMedCrossRef

23.

Walker MJ, Curtis MJ, Hearse DJ, et al. The Lambeth Conventions: guidelines for the study of arrhythmias in ischaemia infarction, and reperfusion. Cardiovasc Res. 1988;22:447–55.PubMedCrossRef

24.

Kirimoto T, Nobori K, Asaka N, Muranaka Y, Tajima K, Miyake H. Beneficial effect of MET-88, a gamma-butyrobetaine hydroxylase inhibitor, on energy metabolism in ischemic dog hearts. Arch Int Pharmacodyn Ther. 1996;331:163–78.PubMed

25.

Ratunova TM, Bauman VR, Kalvin’sh II. The cardioprotective action of carnitine and its structural analog 3-(2, 2, 2-trimethylhydrazine) propionate on cardiac energy metabolism in experimental occlusion of the coronary artery in rats. Farmakol Toksikol. 1989;52:24–7.PubMed

26.

Yonekura K, Eto Y, Yokoyama I, et al. Inhibition of carnitine synthesis modulates protein contents of the cardiac sarcoplasmic reticulum Ca2+-ATPase and hexokinase type I in rat hearts with myocardial infarction. Basic Res Cardiol. 2000;95:343–8.PubMedCrossRef

27.

Liepinsh E, Vilskersts R, Skapare E, et al. Mildronate decreases carnitine availability and up-regulates glucose uptake and related gene expression in the mouse heart. Life Sci. 2008;83:613–9.PubMedCrossRef

28.

Spaniol M, Kaufmann P, Beier K, et al. Mechanisms of liver steatosis in rats with systemic carnitine deficiency due to treatment with trimethylhydraziniumpropionate. J Lipid Res. 2003;44:144–53.PubMedCrossRef

29.

Ferdinandy P, Fazekas T, Kadar E. Effects of orotic acid on ischaemic/reperfused myocardial function and glycogen content in isolated working rat hearts. Pharmacol Res. 1998;37:111–4.PubMedCrossRef

30.

Jasmin G, Proschek L. Effect of orotic acid and magnesium orotate on the development and progression of the UM-X7.1 hamster hereditary cardiomyopathy. Cardiovasc Drugs Ther. 1998;12:189–95.PubMedCrossRef

31.

Donohoe JA, Rosenfeldt FL, Munsch CM, Williams JF. The effect of orotic acid treatment on the energy and carbohydrate metabolism of the hypertrophying rat heart. Int J Biochem. 1993;25:163–82.PubMedCrossRef

32.

Hadj A, Pepe S, Marasco S, Rosenfeldt F. The principles of metabolic therapy for heart disease. Heart Lung Circ. 2003;12:S55–62.PubMedCrossRef

Title: Myocardial Infarct Size-Limiting and Anti-Arrhythmic Effects of Mildronate Orotate in the Rat Heart
Authors: Reinis Vilskersts
Edgars Liepinsh
Janis Kuka
Helena Cirule
Maris Veveris
Ivars Kalvinsh
Maija Dambrova
Publication date: 01-08-2009
Publisher: Springer US
Published in: Cardiovascular Drugs and Therapy / Issue 4/2009
Print ISSN: 0920-3206
Electronic ISSN: 1573-7241
DOI: https://doi.org/10.1007/s10557-009-6179-2

ACC 2024 Congress Coverage

Heart Failure Video

Keynote webinar | Spotlight on sleep in brain health

Springer Medicine

Myocardial Infarct Size-Limiting and Anti-Arrhythmic Effects of Mildronate Orotate in the Rat Heart

Abstract

Purpose

Methods

Results

Conclusions

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page

Keynote webinar | Spotlight on sleep in brain health

Springer Medicine

Abstract

Purpose

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 4/2009

Hyponatremia in Heart Failure: The Role of Arginine Vasopressin and Diuretics

Suppression of Collagen Production in Norepinephrine Stimulated Cardiac Fibroblasts Culture: Differential Effect of α and β-Adrenoreceptor Antagonism

Treatment of Hypertension in Metabolic Syndrome Subjects with Amlodipine and Olmesartan—Effects on Oxidized Non-Esterified Free Fatty Acids and Cytokine Production

Statins and Vitamin D

The President’s Page: Target Response or Target Dose

Response to the Letter of Hester Den Ruijter and Ruben Coronel Regarding the Article “The Role of n-3 PUFAs in Preventing the Arrhythmic Risk in Patients with Idiopathic Dilated Cardiomyopathy”

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page